{"pmid":32414839,"title":"Stability of SARS-CoV-2 in PBS for Molecular Detection.","text":["Stability of SARS-CoV-2 in PBS for Molecular Detection.","RNA viruses often require \"cold-chains\" of transportation to prevent the breakdown of genetic material.....","J Clin Microbiol","Perchetti, Garrett A","Huang, Meei-Li","Peddu, Vikas","Jerome, Keith R","Greninger, Alexander L","32414839"],"abstract":["RNA viruses often require \"cold-chains\" of transportation to prevent the breakdown of genetic material....."],"journal":"J Clin Microbiol","authors":["Perchetti, Garrett A","Huang, Meei-Li","Peddu, Vikas","Jerome, Keith R","Greninger, Alexander L"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414839","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1128/JCM.01094-20","e_drugs":["Lead"],"topics":["Diagnosis"],"weight":1,"_version_":1666994545952292865,"score":9.490897,"similar":[{"pmid":32219885,"title":"Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19.","text":["Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19.","In this study, we collected a total of 610 hospitalized patients from Wuhan between February 2, 2020, and February 17, 2020. We reported a potentially high false negative rate of real-time reverse-transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as computed tomography images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge, and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for the standard of procedures of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well.","J Med Virol","Li, Yafang","Yao, Lin","Li, Jiawei","Chen, Lei","Song, Yiyan","Cai, Zhifang","Yang, Chunhua","32219885"],"abstract":["In this study, we collected a total of 610 hospitalized patients from Wuhan between February 2, 2020, and February 17, 2020. We reported a potentially high false negative rate of real-time reverse-transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as computed tomography images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge, and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for the standard of procedures of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well."],"journal":"J Med Virol","authors":["Li, Yafang","Yao, Lin","Li, Jiawei","Chen, Lei","Song, Yiyan","Cai, Zhifang","Yang, Chunhua"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219885","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25786","keywords":["covid-19","rt-pcr"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492286009344,"score":45.952766},{"pmid":32335089,"pmcid":"PMC7179514","title":"Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.","text":["Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.","BACKGROUND: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA. METHODS: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control. RESULTS: Good correlation of Cq values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (<25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method. CONCLUSION: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians.","Clin Chim Acta","Ishige, Takayuki","Murata, Shota","Taniguchi, Toshibumi","Miyabe, Akiko","Kitamura, Kouichi","Kawasaki, Kenji","Nishimura, Motoi","Igari, Hidetoshi","Matsushita, Kazuyuki","32335089"],"abstract":["BACKGROUND: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA. METHODS: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control. RESULTS: Good correlation of Cq values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (<25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method. CONCLUSION: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians."],"journal":"Clin Chim Acta","authors":["Ishige, Takayuki","Murata, Shota","Taniguchi, Toshibumi","Miyabe, Akiko","Kitamura, Kouichi","Kawasaki, Kenji","Nishimura, Motoi","Igari, Hidetoshi","Matsushita, Kazuyuki"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335089","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.cca.2020.04.023","keywords":["covid-19","high-sensitive","molecular diagnosis","multiplex","sars-cov-2","rrt-pcr"],"locations":["Sarbecovirus"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494101094400,"score":43.55651},{"pmid":32451533,"title":"Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases.","text":["Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases.","OBJECTIVES: To report methods and findings of 2 autopsies with molecular evaluation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive individuals. METHODS: Postmortem examination was completed following Centers for Disease Control and Prevention public guidelines. Numerous formalin-fixed paraffin-embedded (FFPE) tissue types from each case were surveyed for SARS-CoV-2 RNA by quantitative reverse transcription polymerase chain reaction (qRT-PCR). SARS-CoV-2 viral genome was sequenced by next-generation sequencing (NGS) from FFPE lung tissue blocks. RESULTS: Postmortem examinations revealed diffuse alveolar damage, while no viral-associated hepatic, cardiac, or renal damage was observed. Viral RNA was detected in lungs, bronchi, lymph nodes, and spleen in both cases using qRT-PCR method. RNA sequencing using NGS in case 1 revealed mutations most consistent with Western European Clade A2a with ORF1a L3606F mutation. CONCLUSIONS: SARS-CoV-2 testing and viral sequencing can be performed from FFPE tissue. Detection and sequencing of SARS-CoV-2 in combination with morphological findings from postmortem tissue examination can aid in gaining a better understanding of the virus's pathophysiologic effects on human health.","Am J Clin Pathol","Sekulic, Miroslav","Harper, Holly","Nezami, Behtash G","Shen, Daniel L","Sekulic, Simona Pichler","Koeth, Aaron T","Harding, Clifford V","Gilmore, Hannah","Sadri, Navid","32451533"],"abstract":["OBJECTIVES: To report methods and findings of 2 autopsies with molecular evaluation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive individuals. METHODS: Postmortem examination was completed following Centers for Disease Control and Prevention public guidelines. Numerous formalin-fixed paraffin-embedded (FFPE) tissue types from each case were surveyed for SARS-CoV-2 RNA by quantitative reverse transcription polymerase chain reaction (qRT-PCR). SARS-CoV-2 viral genome was sequenced by next-generation sequencing (NGS) from FFPE lung tissue blocks. RESULTS: Postmortem examinations revealed diffuse alveolar damage, while no viral-associated hepatic, cardiac, or renal damage was observed. Viral RNA was detected in lungs, bronchi, lymph nodes, and spleen in both cases using qRT-PCR method. RNA sequencing using NGS in case 1 revealed mutations most consistent with Western European Clade A2a with ORF1a L3606F mutation. CONCLUSIONS: SARS-CoV-2 testing and viral sequencing can be performed from FFPE tissue. Detection and sequencing of SARS-CoV-2 in combination with morphological findings from postmortem tissue examination can aid in gaining a better understanding of the virus's pathophysiologic effects on human health."],"journal":"Am J Clin Pathol","authors":["Sekulic, Miroslav","Harper, Holly","Nezami, Behtash G","Shen, Daniel L","Sekulic, Simona Pichler","Koeth, Aaron T","Harding, Clifford V","Gilmore, Hannah","Sadri, Navid"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451533","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/ajcp/aqaa091","keywords":["autopsy","covid-19","ffpe","molecular testing","sars-cov-2; coronavirus","viral sequencing","ncov-19"],"locations":["bronchi"],"e_drugs":["Paraffin","Formaldehyde"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1667881798526304256,"score":43.161186},{"pmid":32381642,"title":"Understanding, verifying and implementing Emergency Use Authorization molecular diagnostics for the detection of SARS-CoV-2 RNA.","text":["Understanding, verifying and implementing Emergency Use Authorization molecular diagnostics for the detection of SARS-CoV-2 RNA.","The SARS-CoV-2 pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. Acute diagnosis of COVID-19 infection is critically dependent on detection of SARS-CoV-2 RNA from clinical specimens (e.g. nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clinical microbiology laboratories are dependent on commercially available SARS-CoV-2 molecular assays. In contrast to assays approved or cleared by the Food and Drug Administration for in vitro diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have Emergency Use Authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with EUA classification and thus assay verification can be daunting. Further compounding anxiety for laboratories are major issues with supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens.","J Clin Microbiol","Mitchell, Stephanie L","St George, Kirsten","Rhoads, Daniel D","Butler-Wu, Susan M","Dharmarha, Vaishali","McNult, Peggy","Miller, Melissa B","32381642"],"abstract":["The SARS-CoV-2 pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. Acute diagnosis of COVID-19 infection is critically dependent on detection of SARS-CoV-2 RNA from clinical specimens (e.g. nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clinical microbiology laboratories are dependent on commercially available SARS-CoV-2 molecular assays. In contrast to assays approved or cleared by the Food and Drug Administration for in vitro diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have Emergency Use Authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with EUA classification and thus assay verification can be daunting. Further compounding anxiety for laboratories are major issues with supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens."],"journal":"J Clin Microbiol","authors":["Mitchell, Stephanie L","St George, Kirsten","Rhoads, Daniel D","Butler-Wu, Susan M","Dharmarha, Vaishali","McNult, Peggy","Miller, Melissa B"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381642","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/JCM.00796-20","topics":["Diagnosis"],"weight":1,"_version_":1666419683233890305,"score":41.593437}]}